Ascletis Makes Splash with Dual IND Submissions to US FDA for Obesity Treatment
The US FDA is about to get a serious look at two potential obesity treatments from Ascletis, a Chinese biotech. The company has just submitted Investigational New Drug (IND) applications for ASC36, a peptide amylin receptor agonist, and ASC36_35 FDC, a co-formulation of ASC36 and peptide GLP-1R/GIPR agonist ASC35.
ASC36_35 FDC is a potentially first-in-class drug candidate that targets three key areas associated with obesity: the amylin receptor, GLP-1R, and GIPR. This co-formulation has shown impressive results in testing, with approximately 51% of participants experiencing significant weight loss in clinical trials. The once-monthly subcutaneous (SQ) injection offers a convenient and potentially more effective alternative to existing treatments.
What this means: If approved, ASC36 and ASC36_35 FDC could become major players in the fight against obesity. The US FDA’s review process will be closely watched, as these treatments have the potential to transform the way doctors approach weight management.
How These Treatments Work
The development of ASC36 and ASC36_35 FDC represents a significant leap forward in the understanding of obesity and its related biological pathways. By targeting the amylin receptor, GLP-1R, and GIPR, these treatments aim to regulate appetite, glucose metabolism, and energy balance – all critical factors in weight management.
The Implications for Patients
If approved, these treatments could offer patients a new hope in the fight against obesity. The convenience of a once-monthly injection could make it easier for people to stick to their weight management plans, potentially leading to improved health outcomes and reduced reliance on other treatments.
The outcome of the FDA’s review will be crucial in determining the future of ASC36 and ASC36_35 FDC. With approximately 650 million people worldwide living with obesity, the demand for effective treatments is high. Ascletis’s dual IND submissions mark an important milestone in the pursuit of innovative solutions for this pressing global health issue.
